Bcwm LLC purchased a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 31,878 shares of the company’s stock, valued at approximately $935,000.
Other large investors have also added to or reduced their stakes in the company. XXEC Inc. bought a new position in shares of Heartflow during the second quarter valued at about $2,524,764,000. Sei Investments Co. grew its stake in shares of Heartflow by 342.5% in the first quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock worth $1,631,000 after purchasing an additional 51,895 shares during the last quarter. Quantinno Capital Management LP purchased a new position in Heartflow during the 1st quarter valued at about $1,734,000. Handelsbanken Fonder AB purchased a new position in Heartflow during the 2nd quarter valued at about $910,000. Finally, Walleye Capital LLC bought a new position in Heartflow during the 2nd quarter valued at approximately $8,760,000.
Insider Activity at Heartflow
In other Heartflow news, CEO John C.M. Farquhar sold 27,230 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $50.00, for a total transaction of $1,361,500.00. Following the completion of the transaction, the chief executive officer owned 360,814 shares of the company’s stock, valued at approximately $18,040,700. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the sale, the insider owned 86,459 shares in the company, valued at approximately $3,564,704.57. This trade represents a 9.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,271 shares of company stock worth $7,089,136 over the last 90 days. 7.70% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on Heartflow
Heartflow Stock Performance
Heartflow stock opened at $48.94 on Thursday. The stock’s 50 day simple moving average is $31.68 and its two-hundred day simple moving average is $28.79. The stock has a market cap of $4.26 billion and a price-to-earnings ratio of -26.74. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.19.
Heartflow (NASDAQ:HTFL – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The firm had revenue of $64.08 million for the quarter. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current year.
About Heartflow
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
See Also
- Five stocks we like better than Heartflow
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding HTFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heartflow, Inc. (NASDAQ:HTFL – Free Report).
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
